Despite two decades of intensified research to understand and cure tuberculosis disease,
biological uncertainties remain and hamper progress. However, owing to collaborative …

Tuberculosis (TB) remains a leading cause of infectious death worldwide, and poverty is a
major driver. Clinically, TB presents as “latent” TB and active TB disease, and the treatment …

Glomerular disease, be it primary or secondary, occurring in the setting of systemic
autoimmune diseases, infections, drugs, or malignancy, affects individuals of all ages. In …

The introduction and broad use of new immunosuppressive agents, including biologic
agents and JAK inhibitors, have revolutionised treatment of inflammatory bowel disease …

Executive summary Tuberculosis (TB) strains with drug resistance (DR-TB) are more difficult
to treat than drug-susceptible ones, and threaten global progress towards the targets set by …

Comprehensive guidelines for treatment of latent tuberculosis infection (LTBI) among
persons living in the United States were last published in 2000 (American Thoracic Society …

Background Prevention of drug-resistant tuberculosis is a global health priority. However,
trials evaluating the effectiveness of treating Mycobacterium tuberculosis infection among …

The WHO consolidated guidelines on tuberculosis: tuberculosis preventive treatment
provides a comprehensive set of recommendations for programmatic management of …

The current dogma is that 2 billion individuals, making up a quarter of the world's population,
are latently infected with Mycobacterium tuberculosis (1–4). It is thought that latent …

BACKGROUND: Tuberculosis (TB) preventive therapy (TPT) decreases the risk of
develo** TB disease and its associated morbidity and mortality. The aim of these clinical …